| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure SubjectsNCT04318145 | PTN | Phase 2 | Terminated | 2023-12-08Actual |
| Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessNCT04327661 | Vanda Pharmaceuticals | Phase 3 | Completed | 2023-04-01Actual |
| Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNCT04329949 | Corcept Therapeutics | Phase 3 | Terminated | 2021-08-23Actual |
| A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)NCT04336826 | PTC Therapeutics | Phase 2 | Completed | 2023-08-07Actual |
| A Study of Auxora in Patients With Severe COVID-19 PneumoniaNCT04345614 | CALC | Phase 2 | Completed | 2021-06-28Actual |
| Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19NCT04347239 | CytoDyn, Inc. | Phase 2 | Completed | 2021-10-24Actual |
| Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIANCT04360265 | RARE | Phase 3 | Enrolling by invitation | 2027-08Estimated |
| Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH CirrhosisNCT04365868 | GALT | Phase 2, Phase 3 | Terminated | 2025-03-11Actual |
| INB03 for the Treatment of Pulmonary Complications From COVID-19NCT04370236 | INMB | Phase 2, Phase 3 | Terminated | 2021-10-13Actual |
| Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)NCT04371666 | Kyntra Bio | Phase 3 | Terminated | 2023-02-13Actual |
| A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)NCT04374136 | ALEC | Phase 3 | Terminated | 2025-09-01Actual |
| A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyNCT04378075 | PTC Therapeutics | Phase 2, Phase 3 | Terminated | 2023-03-18Actual |
| A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)NCT04379271 | Immunic AG | Phase 2, Phase 3 | Completed | 2021-01-12Actual |
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinNCT04387461 | CGON | Phase 2 | Completed | 2023-03-07Actual |
| Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerNCT04390399 | IBRX | Phase 2 | Active not recruiting | 2025-10-13Actual |
| ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19NCT04393038 | ABVX | Phase 2, Phase 3 | Terminated | 2021-03-05Actual |
| A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion GeneNCT04395677 | NUVB | Phase 2 | Active not recruiting | 2024-06-07Actual |
| Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary FibrosisNCT04396756 | PLRX | Phase 2 | Completed | 2023-02-01Actual |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19NCT04401475 | EDSA | Phase 2, Phase 3 | Terminated | 2024-07-22Actual |
| PH94B in the Treatment of Adjustment Disorder With AnxietyNCT04404192 | VTGN | Phase 2 | Completed | 2022-12-14Actual |
| D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)NCT04411199 | PYPD | Phase 3 | Completed | 2025-04-14Actual |
| Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19NCT04412668 | ATYR | Phase 2 | Completed | 2020-10-23Actual |
| Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus InfectionNCT04412863 | VIR | Phase 2 | Completed | 2024-03-25Actual |
| A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.NCT04414475 | KPTI | Phase 2 | Recruiting | 2028-01Estimated |
| Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal MelanomaNCT04417530 | Aura Biosciences | Phase 2 | Completed | 2024-04-22Actual |
| Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT04419558 | Kyntra Bio | Phase 3 | Terminated | 2023-09-04Actual |
| Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic TreatmentNCT04421456 | Jazz Pharmaceuticals | Phase 2 | Terminated | 2022-03-16Actual |
| Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDSNCT04429555 | MediciNova | Phase 2 | Completed | 2022-06-30Actual |
| A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)NCT04433585 | NKTR | Phase 2 | Completed | 2023-01-10Actual |
| Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyNCT04436029 | Cartesian Therapeutics | Phase 2 | Completed | 2022-02-18Actual |
Trial details
- Registry ID
- NCT04318145
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04327661
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04329949
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04336826
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04345614
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04347239
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04360265
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04365868
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04370236
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04371666
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04374136
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04378075
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04379271
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04387461
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04390399
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04393038
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04395677
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04396756
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04401475
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04404192
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04411199
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04412668
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04412863
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04414475
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04417530
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04419558
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04421456
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04429555
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04433585
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04436029
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.